Subsequent Events (Details Textual)	3 Months Ended			0 Months Ended
	Mar. 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Mar. 31, 2015 EUR (€)	Apr. 15, 2015 Subsequent Event [Member] Employment Agreement [Member] USD ($)	Apr. 15, 2015 Subsequent Event [Member] Employment Agreement [Member] 2015 Equity Incentive Plan [Member] USD ($)	May 04, 2015 Subsequent Event [Member] Second Amendment [Member] USD ($)	May 04, 2015 Subsequent Event [Member] Second Amendment [Member] EUR (€)	May 12, 2015 Subsequent Event [Member] Purchase Agreement [Member] USD ($)
Subsequent Event [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Contractual Term					10 years
Deferred Compensation Arrangement with Individual, Compensation Expense				$ 240,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					2,184,193
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price					$ 0.60
Deferred Compensation Arrangements, Overall, Description				four-year term expiring on April 14, 2019 (the “Term”), unless sooner terminated by either party. Pursuant to the Employment Agreement, Mr. Evans will receive an initial annualized base salary of $240,000 and will be eligible to receive an annual performance bonus of up to 30% of his annualized base salary
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					50% of the options will vest upon the achievement of annual revenue targets of $3,000,000, $6,000,000 and $10,000,000; 15% of the options will vest upon the Company listing on a national securities exchange; and 35% of the options will vest over four years in 16 equal, quarterly installments.
Annual Minimum Amount	1,085,000		1,000,000			1,085,000	1,000,000
Warrants To Purchase Common Stock								900,000
Warrants Exercisable Term								5 years
Stock Issued During Period, Shares, New Issues								1,800,000
Sale of Stock, Price Per Share								$ 0.67
Proceeds from Issuance of Common Stock	$ 0	$ 2,016,000						$ 1,200,000
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.85
Royalty Agreement Commitments Description						the Company and Medica agreed that Italy will continue to be excluded from the worldwide license, and that, until December 31, 2022, the Company will pay Medica a royalty of 3% of net sales, in addition to any other payments required, except that if the Company sublicenses to a third party the right to market and sell its HydraGuard products, the Company will pay Medica a fee of €2.00 (approximately $2.17) per HydraGuard unit in lieu of the 3% royalty.	the Company and Medica agreed that Italy will continue to be excluded from the worldwide license, and that, until December 31, 2022, the Company will pay Medica a royalty of 3% of net sales, in addition to any other payments required, except that if the Company sublicenses to a third party the right to market and sell its HydraGuard products, the Company will pay Medica a fee of €2.00 (approximately $2.17) per HydraGuard unit in lieu of the 3% royalty.